Martin Christian Michel
#107,506
Most Influential Person Now
Researcher
Martin Christian Michel's AcademicInfluence.com Rankings
Martin Christian Michelcomputer-science Degrees
Computer Science
#3967
World Rank
#4171
Historical Rank
Computational Linguistics
#293
World Rank
#298
Historical Rank
Machine Learning
#639
World Rank
#649
Historical Rank
Artificial Intelligence
#838
World Rank
#854
Historical Rank
Download Badge
Computer Science
Martin Christian Michel's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Martin Christian Michel Influential?
(Suggest an Edit or Addition)Martin Christian Michel's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. (2013) (1119)
- XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. (1998) (879)
- Adrenergic and muscarinic receptors in the human heart. (1999) (675)
- The Molecular Basis for the Pharmacokinetics and Pharmacodynamics of Curcumin and Its Metabolites in Relation to Cancer (2014) (399)
- How reliable are G-protein-coupled receptor antibodies? (2009) (288)
- α1‐, α2‐ and β‐adrenoceptors in the urinary bladder, urethra and prostate (2006) (268)
- Are there multiple imidazoline binding sites? (1989) (259)
- A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management--a systematic review and meta-analysis. (2012) (243)
- Behavioral conditioning of immunosuppression is possible in humans (2002) (241)
- Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability (2014) (235)
- A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists (2013) (231)
- Receptors for neuropeptide Y: multiple subtypes and multiple second messengers. (1991) (216)
- THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors (2021) (212)
- Peripheral adrenergic receptors in hypertension. (1990) (194)
- Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. (2006) (191)
- Signal Transduction Underlying Carbachol-Induced Contraction of Human Urinary Bladder (2004) (186)
- Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. (2000) (184)
- Impact of GPCRs in clinical medicine: monogenic diseases, genetic variants and drug targets. (2007) (175)
- Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence (2009) (169)
- Beta-adrenergic receptors in lymphocyte subsets after exercise. Alterations in normal individuals and patients with congestive heart failure. (1990) (163)
- Endogenous nitric oxide and myocardial adaptation to ischemia. (2000) (149)
- A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. (2011) (146)
- Myocardial beta-adrenoceptor changes in heart failure: concomitant reduction in beta 1- and beta 2-adrenoceptor function related to the degree of heart failure in patients with mitral valve disease. (1989) (145)
- M3 muscarinic receptors mediate contraction of human urinary bladder (2002) (143)
- Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors (2009) (143)
- Adrenergic control of circulating lymphocyte subpopulations. Effects of congestive heart failure, dynamic exercise, and terbutaline treatment. (1990) (142)
- Signal transduction mechanisms controlling cardiac contractility and their alterations in chronic heart failure. (1995) (138)
- Mitogen-activated protein kinases in the heart (2001) (136)
- Is the use of parasympathomimetics for treating an underactive urinary bladder evidence‐based? (2007) (131)
- Small and intermediate conductance Ca2+-activated K+ channels confer distinctive patterns of distribution in human tissues and differential cellular localisation in the colon and corpus cavernosum (2004) (130)
- Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and β-adrenoceptors (2007) (126)
- Nerve growth factor in bladder dysfunction: Contributing factor, biomarker, and therapeutic target (2011) (120)
- Elevation of plasma neuropeptide Y levels in congestive heart failure. (1989) (117)
- Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. (1996) (112)
- Association of hypertension with symptoms of benign prostatic hyperplasia. (2004) (112)
- Sphingosine‐1‐phosphate and sphingosylphosphorylcholine constrict renal and mesenteric microvessels in vitro (2000) (109)
- Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? (1998) (107)
- Does gender or age affect the efficacy and safety of tolterodine? (2002) (104)
- A polymorphism in the gene for the angiotensin II type 1 receptor is not associated with hypertension (1997) (104)
- A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder. (2012) (104)
- Flexible‐Dose Fesoterodine in Elderly Adults with Overactive Bladder: Results of the Randomized, Double‐Blind, Placebo‐Controlled Study of Fesoterodine in an Aging Population Trial (2013) (103)
- Catecholamines increase lymphocyte beta 2-adrenergic receptors via a beta 2-adrenergic, spleen-dependent process. (1990) (102)
- Neuropeptide Y: a possible role in hypertension? (1995) (100)
- Neuropeptide Y mobilizes Ca2+ and inhibits adenylate cyclase in human erythroleukemia cells. (1988) (98)
- Profound Increase in Epinephrine Concentration in Plasma and Cardiovascular Stimulation after [micro sign]‐Opioid Receptor Blockade in Opioid‐addicted Patients during Barbiturate‐induced Anesthesia for Acute Detoxification (1998) (97)
- Saw palmetto extracts potently and noncompetitively inhibit human α1‐adrenoceptors in vitro (1999) (96)
- Successful pharmacologic treatment of major depressive disorder attenuates amygdala activation to negative facial expressions: a functional magnetic resonance imaging study. (2012) (96)
- A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer (2014) (96)
- A Double-Blind Comparison of Terazosin and Tamsulosin on Their Differential Effects on Ambulatory Blood Pressure and Nocturnal Orthostatic Stress Testing (1998) (96)
- Rho kinase: a target for treating urinary bladder dysfunction? (2006) (95)
- Sequence of echocardiographic changes during development of right ventricular failure in rat. (2006) (95)
- Tools to study β3-adrenoceptors (2007) (94)
- Regulation of G protein-coupled receptor signalling: focus on the cardiovascular system and regulator of G protein signalling proteins. (2008) (93)
- Physiological and pathological regulation of the autonomic control of urinary bladder contractility. (2008) (93)
- Comparison of problem-and lecture-based pharmacology teaching. (2002) (93)
- Prevalence and physician awareness of symptoms of urinary bladder dysfunction. (2002) (90)
- Inconsistent relation of MAPK activation to infarct size reduction by ischemic preconditioning in pigs. (2000) (90)
- Effects of α1-Adrenoceptor Antagonists on Male Sexual Function (2012) (89)
- Spare Receptors for β‐Adrenoceptor-Mediated Positive Inotropic Effects of Catecholamines in the Human Heart (1992) (88)
- Sphingosine‐1‐phosphate reduces rat renal and mesenteric blood flow in vivo in a pertussis toxin‐sensitive manner (2000) (87)
- p38 MAP kinase is a mediator of ischemic preconditioning in pigs. (2002) (87)
- In-vivo studies do not support a major functional role for the Gly389Arg beta 1-adrenoceptor polymorphism in humans. (2001) (85)
- Guidelines on Benign Prostatic Hyperplasia (2006) (82)
- Human heart β-adrenoceptors: A fair comparison with lymphocyte β-adrenoceptors? (1987) (81)
- Drug- and disease-induced changes of human cardiac β1- and β2-adrenoceptors (1989) (81)
- Keeping an eye on the I site: imidazoline-preferring receptors. (1992) (79)
- Cyclic AMP-dependent and Epac-mediated Activation of R-Ras by G Protein-coupled Receptors Leads to Phospholipase D Stimulation* (2006) (78)
- How valid are animal models to evaluate treatments for pulmonary hypertension? (2006) (78)
- Beta-adrenoceptor regulation in the human heart: can it be monitored in circulating lymphocytes? (1989) (78)
- Does Cyclic AMP Mediate Rat Urinary Bladder Relaxation by Isoproterenol? (2005) (77)
- Arterial hypotension in chronic hemodialyzed patients. (1987) (77)
- M(3) muscarinic receptors mediate contraction of human urinary bladder. (2002) (77)
- An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system (2001) (76)
- Is α1D-adrenoreptor protein detactable in rat tissues? (1997) (75)
- Signal Transduction Underlying Carbachol-Induced Contraction of Rat Urinary Bladder. I. Phospholipases and Ca2+ Sources (2004) (75)
- Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome (2013) (73)
- Biased Agonism in Drug Discovery—Is It Too Soon to Choose a Path? (2018) (72)
- The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers. (2001) (72)
- Alpha 1-adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Evidence for heterogeneity of chloroethylclonidine-resistant rat renal alpha 1-adrenoceptor. (1993) (71)
- Safety of Telmisartan in Patients with Arterial Hypertension (2004) (70)
- Acute detoxification of opioid‐addicted patients with naloxone during propofol or methohexital anesthesia: A comparison of withdrawal symptoms, neuroendocrine, metabolic, and cardiovascular patterns (2000) (69)
- Classification of α1-adrenoceptor subtypes (1995) (69)
- Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome (2008) (68)
- Comparison of human α1-adrenoceptor subtype coupling to protein kinase C activation and related signalling pathways (1998) (67)
- Gender comparison of muscarinic receptor expression and function in rat and human urinary bladder: differential regulation of M2 and M3 receptors? (2003) (66)
- Basic mechanisms of urgency: preclinical and clinical evidence. (2009) (66)
- Adrenergic receptors and their signal transduction mechanisms in hypertension. (1992) (66)
- Signal Transduction Underlying Carbachol-Induced Contraction of Rat Urinary Bladder. II. Protein Kinases (2004) (65)
- Neuropeptide Y 3–36 is an endogenous ligand selective for Y2 receptors (1996) (65)
- Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes. (1997) (64)
- Do α1‐adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? (2008) (64)
- Epac and the cardiovascular system. (2007) (63)
- The Odd Sibling: Features of β3-Adrenoceptor Pharmacology (2014) (62)
- Renal effects of neuropeptide Y (1998) (62)
- Opportunities and Challenges for Drug Development: Public–Private Partnerships, Adaptive Designs and Big Data (2016) (61)
- Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. (1998) (60)
- Cardiovascular Safety and Overall Tolerability of Solifenacin in Routine Clinical Use (2008) (60)
- Pharmacologic treatment of male stress urinary incontinence: systematic review of the literature and levels of evidence. (2008) (59)
- Neuropeptide Y and Related Peptides (2004) (59)
- Cholinergic innervation and muscarinic receptors in the human prostate. (2008) (59)
- Catecholamines increase lymphocyte β2-adrenergic receptors via a β2-adrenergic, spleen-dependent process (1990) (58)
- Tamsulosin: Real Life Clinical Experience in 19,365 Patients (1998) (58)
- Evidence Why Paroxetine Dose Escalation is Not Effective in Major Depressive Disorder: A Randomized Controlled Trial With Assessment of Serotonin Transporter Occupancy (2009) (58)
- Selective irreversible binding of chloroethylclonidine at alpha 1- and alpha 2-adrenoceptor subtypes. (1993) (58)
- The role of nocturia in the quality of life of men with lower urinary tract symptoms (2010) (58)
- Myocardial dysfunction in donor hearts. A possible etiology. (1999) (58)
- Racemic Ketamine Decreases Muscle Sympathetic Activity but Maintains the Neural Response to Hypotensive Challenges in Humans (2000) (57)
- Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease. (2016) (57)
- Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system (2005) (57)
- Radioligand binding studies of α1‐adrenoceptor subtypes in rat heart (1994) (57)
- Signal transduction and regulation: are all alpha1-adrenergic receptor subtypes created equal? (2007) (56)
- Endothelin-A receptor antagonist inhibits angiotensin II and noradrenaline in man. (2001) (55)
- Effects of gender, age and hypertension on β-adrenergic receptor function in rat urinary bladder (2006) (55)
- Treatment of the overactive bladder syndrome with muscarinic receptor antagonists - a matter of metabolites? (2006) (55)
- A Comprehensive Review of the Pharmacodynamics, Pharmacokinetics, and Clinical Effects of the Neutral Endopeptidase Inhibitor Racecadotril (2012) (55)
- Long‐term safety, tolerability and efficacy of flexible‐dose fesoterodine in elderly patients with overactive bladder: Open‐label extension of the SOFIA trial (2014) (54)
- Muscarinic receptor subtypes in porcine detrusor: comparison with humans and regulation by bladder augmentation (1998) (54)
- Neuropeptide Y Receptors (2008) (54)
- Murine alpha1-adrenoceptor subtypes. I. Radioligand binding studies. (1998) (54)
- Worldwide experience with alfuzosin and tamsulosin. (2001) (54)
- Regulation of cardiac beta-adrenergic receptors by captopril. Implications for congestive heart failure. (1989) (54)
- The Pharmacokinetic Profile of Tamsulosin Oral Controlled Absorption System (OCAS (2005) (54)
- Receptor subtypes Y1 and Y5 are involved in the renal effects of neuropeptide Y (1997) (53)
- Drug-Induced Urinary Incontinence (2015) (53)
- Comparison of three radioligands for the labelling of human β-adrenoceptor subtypes (2006) (53)
- Sphingosine Kinase–Dependent Activation of Endothelial Nitric Oxide Synthase by Angiotensin II (2006) (53)
- Pharmacokinetics and Pharmacodynamics of Tamsulosin in its Modified-Release and Oral Controlled Absorption System Formulations (2010) (53)
- Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder (2009) (52)
- Effects of ageing on muscarinic receptor subtypes and function in rat urinary bladder (2005) (51)
- Nocturia: A non‐specific but important symptom of urological disease (2009) (51)
- Effects of alpha(1)-adrenoceptor antagonists on male sexual function. (2006) (50)
- A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans (2015) (50)
- A 6-month large-scale study into the safety of tamsulosin. (2001) (49)
- Medical Expulsive Therapy for Distal Ureteral Stones (2012) (49)
- Renal α‐adrenergic receptor alterations: a cause of essential hypertension? (1989) (49)
- Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. (2008) (48)
- Decreased myometrial β‐adrenoceptors in women receiving β2‐adrenergic tocolytic therapy: Correlation with lymphocyte β‐adrenoceptors (1989) (48)
- The pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder disease☆ (2014) (48)
- Pharmacogenetics of hypertension treatment: a structured review. (2003) (48)
- Tocolytic therapy with fenoterol induces selective down-regulation of beta-adrenergic receptors in human myometrium. (1997) (48)
- L-type calcium current and contractility in ventricular myocytes from mice overexpressing the cardiac β2-adrenoceptor (1999) (48)
- Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder. (2005) (47)
- Effect of the C825T Polymorphism of the G Protein β3 Subunit on the Systolic Blood Pressure–Lowering Effect of Clonidine in Young, Healthy Male Subjects (2003) (46)
- Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years. (2012) (46)
- β3-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in a repositioning clinical drug development project. (2016) (46)
- Guidelines on the Treatment of Non-neurogenic Male LUTS (2011) (45)
- Effect of pre-contraction on β-adrenoceptor-mediated relaxation of rat urinary bladder (2009) (45)
- Are cardiac G-proteins altered in rat models of hypertension? (1993) (44)
- alpha(1)-adrenoceptor subtypes differentially couple to growth promotion and inhibition in Chinese hamster ovary cells. (2000) (44)
- Ontogenesis of sympathetic responsiveness in spontaneously hypertensive rats. II. Renal G proteins in male and female rats. (1994) (44)
- Do gene polymorphisms alone or in combination affect the function of human β3‐adrenoceptors? (2009) (43)
- Agonist-induced desensitization of beta-adrenoceptor function in humans. Subtype-selective reduction in beta 1- or beta 2-adrenoceptor-mediated physiological effects by xamoterol or procaterol. (1990) (43)
- Tissue functions mediated by β3-adrenoceptors—findings and challenges (2010) (43)
- New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology (2019) (42)
- Autonomic nervous control of the urinary bladder (2013) (42)
- Is alpha1D-adrenoceptor protein detectable in rat tissues? (1997) (42)
- The effect of bladder outlet obstruction on α1‐ and β‐adrenoceptor expression and function (2009) (42)
- Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms (2014) (42)
- Distinction of NPY receptors in vitro and in vivo. I. NPY-(18-36) discriminates NPY receptor subtypes in vitro. (1990) (41)
- Receptor systems in the non-failing human heart. (1992) (41)
- More severe cellular phenotype in human idiopathic dilated cardiomyopathy compared to ischemic heart disease (2010) (40)
- Cyclic AMP counteracts mitogen‐induced inositol phosphate generation and increases in intracellular Ca2+ concentrations in human lymphocytes (1991) (40)
- New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology (2019) (40)
- Chronic treatment with carbachol sensitizes the myocardium to cAMP-induced arrhythmia. (1996) (40)
- Classification of alpha 1-adrenoceptor subtypes. (1995) (39)
- Ligand-Directed Signaling: 50 Ways to Find a Lover (2007) (39)
- Guidelines on Conservative Treatment of Non-neurogenic Male LUTS (2010) (39)
- Functional studies on α1‐adrenoceptor subtypes mediating inotropic effects in rat right ventricle (1994) (39)
- Cardiac hypertrophy in the dog and rat induced by oxfenicine, an agent which modifies muscle metabolism. (1984) (39)
- The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: alpha-blockers in the treatment of male voiding dysfunction - how do they work and why do they differ in tolerability? (2010) (39)
- Muscarinic receptor antagonists for overactive bladder treatment: does one fit all? (2009) (39)
- Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk (2007) (38)
- Problem- vs. lecture-based pharmacology teaching in a German medical school (2002) (38)
- Expression profiling of G‐protein‐coupled receptors in human urothelium and related cell lines (2012) (38)
- Functional investigation of β-adrenoceptors in human isolated detrusor focusing on the novel selective β3-adrenoceptor agonist KUC-7322 (2012) (37)
- Agonist high- and low-affinity states of dopamine D2 receptors: methods of detection and clinical implications (2013) (37)
- Differential regulation of human α1-adrenoceptor subtypes (1999) (37)
- Tools to study beta3-adrenoceptors. (2007) (37)
- The β3‐adrenoceptor agonist mirabegron increases human atrial force through β1‐adrenoceptors: an indirect mechanism? (2017) (36)
- Chronic μ-Opioid Receptor Stimulation in Humans Decreases Muscle Sympathetic Nerve Activity (2001) (36)
- α‐Blockers and lower urinary tract function: more than smooth muscle relaxation? (2000) (36)
- Concomitant Endocrine and Immune Alterations during Alcohol Intoxication and Acute Withdrawal in Alcohol-Dependent Subjects (2002) (36)
- In vivo studies on the effects of α1-adrenoceptor antagonists on pupil diameter and urethral tone in rabbits (2006) (35)
- Lysosphingolipid receptor‐mediated diuresis and natriuresis in anaesthetized rats (2001) (35)
- Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. (2011) (35)
- α2-Adrenoceptors in opossum kidney cells couple to stimulation of mitogen-activated protein kinase independently of adenylyl cyclase inhibition (1997) (35)
- The neuro-urological connection (2005) (34)
- Effects of voluntary dose escalation in a placebo‐controlled, flexible‐dose trial of fesoterodine in subjects with overactive bladder (2011) (34)
- Emerging functions for neuropeptide Y5 receptors. (1999) (34)
- Systematic review of guidelines for internal validity in the design, conduct and analysis of preclinical biomedical experiments involving laboratory animals (2020) (33)
- Are there functional β3‐adrenoceptors in the human heart? (2011) (33)
- Pharmacogenomics of G Protein-Coupled Receptor Ligands in Cardiovascular Medicine (2008) (33)
- Neuropeptide-Y stimulation of extracellular signal-regulated kinases in human erythroleukemia cells. (1999) (33)
- Role of muscarinic receptor antagonists in urgency and nocturia (2005) (33)
- Growth factor-like action of lysophosphatidic acid on human B lymphoblasts. (1998) (33)
- Lymphocyte beta 2-adrenoceptors mirror precisely beta 2-adrenoceptor, but poorly beta 1-adrenoceptor changes in the human heart. (1986) (32)
- Treatment Satisfaction of Patients with Lower Urinary Tract Symptoms: Randomised Controlled Trials vs. Real Life Practice (2000) (32)
- Characterization of alpha-adrenoceptor subtypes in the corpus cavernosum of patients undergoing sex change surgery. (1999) (32)
- Stimulation of alpha1A-adrenoceptors in Rat-1 cells inhibits extracellular signal-regulated kinase by activating p38 mitogen-activated protein kinase. (1998) (32)
- Cardiovascular Safety of the Oral Controlled Absorption System (OCAS) Formulation of Tamsulosin Compared to the Modified Release (MR) Formulation (2005) (32)
- Extracts from Rhois aromatica and Solidaginis virgaurea inhibit rat and human bladder contraction (2004) (31)
- Does Phospholipase C Mediate Muscarinic Receptor-Induced Rat Urinary Bladder Contraction? (2007) (31)
- Sympathetic Neural Activation Evoked by &mgr;-Receptor Blockade in Patients Addicted to Opioids Is Abolished by Intravenous Clonidine (2002) (31)
- Neuropeptide Y (NPY) receptors in HEL cells: comparison of binding and functional parameters for full and partial agonists and a non‐peptide antagonist (1992) (31)
- Lack of inotropic effects of neuropeptide Y in human myocardium. (1989) (31)
- New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology (2019) (31)
- Ontogenesis of sympathetic responsiveness in spontaneously hypertensive rats. I. Renal alpha 1-, alpha 2-, and beta-adrenergic receptors and their signaling. (1993) (31)
- A rapid and validated HPLC method to quantify sphingosine 1-phosphate in human plasma using solid-phase extraction followed by derivatization with fluorescence detection. (2005) (31)
- Cardiovascular Safety of Tamsulosin Modified Release in the Fasted and Fed State in Elderly Healthy Subjects (2005) (31)
- Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome – insight from transcriptosome and experimental studies (2016) (30)
- Lack of evidence that nebivolol is a β₃-adrenoceptor agonist. (2011) (30)
- A role for muscarinic receptors or rho-kinase in hypertension associated rat bladder dysfunction? (2005) (30)
- β-Adrenergic Receptor Subtypes in the Urinary Tract. (2011) (30)
- Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients (2007) (30)
- Good Research Practice in Non-Clinical Pharmacology and Biomedicine (2020) (30)
- Comparison of the positive inotropic effects of serotonin, histamine, angiotensin II, endothelin and isoprenaline in the isolated human right atrium (1993) (30)
- Does [3H]2-methoxy-idazoxan (RX 821002) detect more alpha-2-adrenoceptor agonist high-affinity sites than [3H]rauwolscine? A comparison of nine tissues and cell lines. (1995) (30)
- Basic mechanisms of urgency: roles and benefits of pharmacotherapy (2009) (30)
- In vitro and in vivo uroselectivity of B8805-033, an antagonist with high affinity at prostatic α1A- vs. α1B- and α1D-adrenoceptors (2001) (29)
- Do β-adrenoceptor agonists induce homologous or heterologous desensitization in rat urinary bladder? (2014) (29)
- Alpha and beta-adrenoceptors in hypertension. I. Cardiac and renal alpha 1-, beta 1-, and beta 2-adrenoceptors in rat models of acquired hypertension. (1989) (29)
- Propranolol treatment affects parameters of human immunity. (1991) (29)
- Does concomitant stress incontinence alter the efficacy of tolterodine in patients with overactive bladder? (2004) (29)
- Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction (2009) (29)
- Effect of short-term outlet obstruction on rat bladder nerve density and contractility. (2007) (29)
- NPY Receptor Subtypes and Their Signal Transduction (2004) (29)
- β-adrenoceptor agonist effects in experimental models of bladder dysfunction. (2011) (29)
- Pertussis toxin treatment of whole blood. A novel approach to assess G protein function in congestive heart failure. (1990) (29)
- Prejunctional neuropeptide Y receptors in human kidney and atrium. (1997) (29)
- The beta2-adrenoceptor gene and hypertension: is it the promoter or the coding region or neither? (2006) (28)
- Differentiation of β1- and β2-adrenoceptor-mediated effects in humans (1988) (28)
- Beta-2 adrenoceptor-mediated relaxation of the isolated human saphenous vein. (1987) (28)
- Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic efficacy. (1992) (27)
- β3‐Adrenoceptors in the normal and diseased urinary bladder—What are the open questions? (2019) (27)
- A systematic review of urinary bladder hypertrophy in experimental diabetes: Part 2. Comparison of animal models and functional consequences (2018) (27)
- Haemodynamic characterization of young normotensive men carrying the 825T-allele of the G-protein beta3 subunit. (2001) (27)
- Subtype-selective modulation of human beta 1- and beta 2-adrenoceptor function by beta-adrenoceptor agonists and antagonists. (1990) (27)
- Vasoconstriction of rat renal interlobar arteries by noradrenaline and neuropeptide Y. (1997) (27)
- Functional correlates of α2A-adrenoceptor gene polymorphism in the HANE study (1999) (26)
- Modulation of lower urinary tract smooth muscle contraction and relaxation by the urothelium (2018) (26)
- Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. (2009) (26)
- Dynamic exercise‐induced increase in lymphocyte beta‐2‐adrenoceptors: Abnormality in essential hypertension and its correction by antihypertensives (1987) (26)
- Differential vascular α1‐adrenoceptor antagonism by tamsulosin and terazosin (1999) (26)
- The new radioligand [(3)H]-L 748,337 differentially labels human and rat β3-adrenoceptors. (2013) (25)
- Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism? (2008) (25)
- Adrenoceptors mediating the cardiovascular and metabolic effects of alpha-methylnoradrenaline in humans. (1999) (25)
- Comparison of Vascular α1-Adrenoceptor Antagonism of Tamsulosin in Oral Controlled Absorption System (OCAS) and Modified Release (MR) Formulations (2005) (24)
- Nifedipine inhibits sphingosine-1-phosphate-induced renovascular contraction in vitro and in vivo (2001) (24)
- A Benefit-Risk Assessment of Extended-Release Oxybutynin (2002) (24)
- Differential calcium signalling by m2 and m3 muscarinic acetylcholine receptors in a single cell type (1995) (24)
- Different muscarinic receptor subtypes modulate proliferation of primary human detrusor smooth muscle cells via Akt/PI3K and map kinases. (2013) (23)
- Comparison of signalling mechanisms involved in rat mesenteric microvessel contraction by noradrenaline and sphingosylphosphorylcholine (2003) (23)
- Muscarinic receptor subtypes and signalling involved in the attenuation of isoprenaline-induced rat urinary bladder relaxation (2011) (23)
- [Benign prostate hyperplasia]. (2006) (23)
- Alpha1-adrenoceptors and ejaculatory function. (2007) (23)
- Therapeutic modulation of urinary bladder function: multiple targets at multiple levels. (2015) (23)
- Alpha- and beta-adrenoceptors in hypertension. II. Platelet alpha 2- and lymphocyte beta 2-adrenoceptors in children of parents with essential hypertension. A model for the pathogenesis of the genetically determined hypertension. (1989) (23)
- Effects of noradrenaline and neuropeptide Y on rat mesenteric microvessel contraction (1996) (23)
- Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction – What’s the Long-Term Effectiveness of Medical Therapies? (2001) (23)
- Effect of prednisolone and ketotifen onβ2-adrenoceptors in asthmatic patients receivingβ2-bronchodilators (2004) (23)
- Mitigation of beta 1- and/or beta 2-adrenoceptor function in human heart failure. (1990) (23)
- Prolonged Isoproterenol Treatment Alters Immunoregulatory Cell Traffic and Function in the Rat (1993) (22)
- Receptor and Binding Studies (2005) (22)
- Transient receptor potential vanilloid 1 mediates nerve growth factor‐induced bladder hyperactivity and noxious input (2012) (22)
- Do saw palmetto extracts block humanα1‐adrenoceptor subtypes in vivo? (2001) (22)
- Limited signal transduction repertoire of human Y5 neuropeptide Y receptors expressed in HEC-1B cells (2001) (22)
- Muscarinic receptors stimulate cell proliferation in the human urothelium-derived cell line UROtsa. (2011) (22)
- α-Blocker Treatment of Urolithiasis (2006) (22)
- S1P receptor signalling and RGS proteins; expression and function in vascular smooth muscle cells and transfected CHO cells. (2008) (22)
- Apoptosis induction by doxazosin and other quinazoline α1-adrenoceptor antagonists: a new mechanism for cancer treatment? (2009) (22)
- On the role of renal alpha-adrenergic receptors in spontaneously hypertensive rats. (1992) (21)
- Alpha2B-adrenoceptors couple to Ca2+ increase in both endogenous and recombinant expression systems. (1998) (21)
- Differentiation of beta 1- and beta 2-adrenoceptor-mediated effects in humans. (1988) (21)
- A systematic review of urinary bladder hypertrophy in experimental diabetes: Part I. Streptozotocin‐induced rat models (2018) (21)
- Comparison of noradrenaline and lysosphingolipid-induced vasoconstriction in mouse and rat small mesenteric arteries. (2004) (21)
- Hunting for the high‐affinity state of G‐protein‐coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging (2018) (21)
- Alpha 1-adrenoceptor subtypes in the human cardiovascular and urogenital systems. (1998) (21)
- α‐ and β‐Adrenoceptors in Hypertension: Molecular Biology and Pharmacological Studies (1992) (20)
- Selectivity of pharmacological tools: implications for use in cell physiology. A review in the theme: Cell signaling: proteins, pathways and mechanisms. (2015) (20)
- Are polymorphisms of the β3‐adrenoceptor gene associated with an altered bladder function? (2013) (20)
- Efficacy of propiverine ER with or without α-blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study (2011) (20)
- Potential Role of α1-Adrenoceptors in the Aetiology of LUTS (2002) (20)
- β3-Adrenoceptor-mediated relaxation of rat and human urinary bladder: roles of BKCa channels and Rho kinase (2015) (20)
- Therapeutic targets for overactive bladder other than smooth muscle (2015) (20)
- Similarities and differences in the autonomic control of airway and urinary bladder smooth muscle (2008) (20)
- Are blood vessels a target to treat lower urinary tract dysfunction? (2015) (20)
- Agonist-induced desensitization of human β3-adrenoceptors expressed in human embryonic kidney cells (2013) (20)
- Prejunctional and peripheral effects of the cannabinoid CB1 receptor inverse agonist rimonabant (SR 141716) (2008) (20)
- Lower Urinary Tract Symptoms: What's New in Medical Treatment? (2018) (19)
- Transient relaxation of rat mesenteric microvessels by ceramides (2002) (19)
- Agonist‐induced desensitisation of β3‐adrenoceptors: Where, when, and how? (2019) (19)
- Comparison of cloned and pharmacologically defined rat tissue α1-adrenoceptor subtypes (1994) (19)
- S (+)-Ketamine Increases Muscle Sympathetic Activity and Maintains the Neural Response to Hypotensive Challenges in Humans (2001) (19)
- Efficacy and safety of tamsulosin in the treatment of urological diseases (2004) (19)
- Beta-adrenergic receptors in congestive heart failure: present knowledge and future directions. (1989) (19)
- Distinction of NPY receptors in vitro and in vivo. II. Differential effects of NPY and NPY-(18-36). (1990) (19)
- Human Urinary Bladder Strip Relaxation by the β-Adrenoceptor Agonist Isoprenaline: Methodological Considerations and Effects of Gender and Age (2011) (19)
- Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL). (2006) (19)
- Beta-adrenoceptor control of immune function in congestive heart failure. (1990) (19)
- a 1 -, a 2 - and b -adrenoceptors in the urinary bladder, urethra and prostate (2006) (18)
- Is PP56 (D-myo-inositol-1,2,6-trisphosphate) an antagonist at neuropeptide Y receptors? (1993) (18)
- Neuropeptide Y lowers blood glucose in anaesthetized rats via a Y5 receptor subtype. (1998) (18)
- Norepinephrine and Neuropeptide Y Increase Intracellular Ca2+ in Cultured Porcine Aortic Smooth Muscle Cells (1993) (18)
- [Therapy of benign prostate syndrome (BPS): guidelines of the German Urologists (DGU)]. (2009) (18)
- Does the Number of Previous Vaginal Deliveries Affect Overactive Bladder Symptoms and their Response to Treatment? (2008) (18)
- Validation of a rapid, non-radioactive method to quantify internalisation of G-protein coupled receptors (2007) (18)
- Cognitive and mood side effects of lower urinary tract medication (2019) (18)
- Differential agonist-induced regulation of human M2 and M3 muscarinic receptors. (2003) (17)
- Cardiac β3‐adrenoceptors—A role in human pathophysiology? (2019) (17)
- Factors associated with efficacy of an ibuprofen/pseudoephedrine combination drug in pharmacy customers with common cold symptoms (2016) (17)
- An Extract From the Bark of Aspidosperma Quebracho Blanco Binds to Human Penile α-Adrenoceptors (2002) (17)
- Comparison of guinea‐pig, bovine and rat α1‐adrenoceptor subtypes (1996) (17)
- Indomethacin differentiates the renal effects of sphingosine-1-phosphate and sphingosylphosphorylcholine (2006) (17)
- The RhoA/Rho kinase pathway in the myocardium. (2007) (17)
- The Pharmacological Profile of the a 1A-Adrenoceptor Antagonist Silodosin (2010) (17)
- Selective regulation of beta 1- and beta 2-adrenoceptors in the human heart by chronic beta-adrenoceptor antagonist treatment. (1988) (17)
- A quantitative analysis of antagonism and inverse agonism at wild-type and constitutively active hamster α1B-adrenoceptors (2000) (17)
- The Y1 antagonist BIBP 3226 inhibits potentiation of methoxamine-induced vasoconstriction by neuropeptide Y (1997) (17)
- Erratum to: Rat β3-adrenoceptor protein expression: antibody validation and distribution in rat gastrointestinal and urogenital tissues (2014) (17)
- Differential alpha1-adrenoceptor labeling by [3H]prazosin and [3H]tamsulosin. (1998) (17)
- Regulation of NPY/NPY Y1 receptor/G protein system in rat brain cortex. (1995) (16)
- Chronic mu-opioid receptor stimulation in humans decreases muscle sympathetic nerve activity. (2001) (16)
- Modulation of noradrenaline-induced microvascular constriction by protein kinase inhibitors (2000) (16)
- The α1B‐adrenoceptor subtype mediates adrenergic vasoconstriction in mouse retinal arterioles with damaged endothelium (2014) (16)
- Expression of renal alpha 1-adrenergic receptor subtypes in established hypertension. (1992) (16)
- Muscarinic type-1 receptors contribute to IK,ACh in human atrial cardiomyocytes and are upregulated in patients with chronic atrial fibrillation. (2017) (16)
- Concomitant regulation of Ca2+ mobilization and G13 expression in human erythroleukemia cells. (1998) (16)
- Dynamic bias and its implications for GPCR drug discovery (2014) (16)
- alpha-Adrenergic regulation of human renal function. (1996) (16)
- Decreased myometrial beta-adrenoceptors in women receiving beta 2-adrenergic tocolytic therapy: correlation with lymphocyte beta-adrenoceptors. (1989) (16)
- [Diagnostic and differential diagnosis of benign prostate syndrome (BPS): guidelines of the German Urologists]. (2009) (16)
- Receptor gene polymorphisms: lessons on functional relevance from the β1‐adrenoceptor (2003) (16)
- Increased neuropeptide Y-like immunoreactivity in cerebrospinal fluid and plasma of human immunodeficiency virus-infected patients: relationship to HIV encephalopathy (1996) (16)
- Indomethacin inhibits the natriuretic effects of neuropeptide Y in anesthetized rats. (1998) (16)
- Lack of neuropeptide Y receptor detection in human bladder and prostate (2000) (15)
- Novel muscarinic antagonists to treat incontinence and/or overactive bladder ☆ (2005) (15)
- Are RGS2 gene polymorphisms associated with high blood pressure in an ethnicity- and gender-specific manner? (2009) (15)
- Renovascular and tubular effects of neuropeptide Y are discriminated by PP56 (D-myo-inositol 1,2,6-triphosphate) in anaesthetized rats (1997) (15)
- The muscarinic receptor antagonist propiverine exhibits α1-adrenoceptor antagonism in human prostate and porcine trigonum (2011) (15)
- Rat β3-adrenoceptor protein expression: antibody validation and distribution in rat gastrointestinal and urogenital tissues (2014) (15)
- Characterization of differential patient profiles and therapeutic responses of pharmacy customers for four ambroxol formulations (2018) (14)
- Thyroid status affects the rat cardiac beta-adrenoceptor system transiently and time-dependently. (1998) (14)
- 21st century headache: mapping new territory (2021) (14)
- The role of cyclic AMP in the positive inotropic effect mediated by β1- and β2-adrenoceptors in isolated human right atrium (1987) (14)
- Synthesis and characterization of a novel series of agonist compounds as potential radiopharmaceuticals for imaging dopamine D₂/₃ receptors in their high-affinity state. (2014) (14)
- Do overactive bladder symptoms and their treatment‐associated changes exhibit a normal distribution? Implications for analysis and reporting (2020) (14)
- Understanding Dose Titration: Overactive Bladder Treatment With Fesoterodine as an Example (2011) (13)
- Possible mechanism of the negative inotropic effect of α1‐adrenoceptor agonists in rat isolated left atria after exposure to free radicals (1998) (13)
- Growth factor-like action of lysophosphatidic acid on human B lymphoblasts. (1998) (13)
- Correlation between human myometrial and platelet alpha 2-adrenoceptor density. (1988) (13)
- Differential regulation of 46 and 54 kDa jun N-terminal kinases and p38 mitogen-activated protein kinase by human alpha(1A)-adrenoceptors expressed in Rat-1 cells. (1999) (13)
- Was bedeutet das „intraoperative floppy iris“ Syndrom für den Urologen? (2006) (13)
- Effects of sphingosine-1-phosphate and sphingosylphosphorylcholine on intracellular Ca2+ and cell death in prostate cancer cell lines. (2007) (13)
- [Guidelines for German urologists on diagnosis of benign prostate syndrome]. (2003) (13)
- [Pro34]peptide YY is a Y1-selective agonist at peptide YY/neuropeptide Y receptors. (1994) (13)
- cAMP-independent relaxation of smooth muscle cells via Gs-coupled receptors (2003) (13)
- Non-peptide neuropeptide y antagonists derived from the histamine H2 agonist arpromidine: Role of the guanidine group (1995) (13)
- Properties of alpha 2-adrenoceptors in human myometrium and kidney: similarities with human platelets, but differences in the rat kidney. (1989) (13)
- Bradykinin Contracts Rat Urinary Bladder Largely Independently of Phospholipase C (2014) (13)
- Which single‐item measures of overactive bladder symptom treatment correlate best with patient satisfaction? (2011) (12)
- An extract from the bark of Aspidosperma quebracho blanco binds to human penile alpha-adrenoceptors. (2002) (12)
- Desirable properties of β3-adrenoceptor agonists: implications for the selection of drug development candidates. (2011) (12)
- β-adrenoceptor desensitization in SK-N-MC cells, a human cell line containing a homogeneous population of β1-adrenoceptors (1993) (12)
- Functional correlates of alpha(2A)-adrenoceptor gene polymorphism in the HANE study. (1999) (12)
- Bradykinin may be involved in neuropeptide Y-induced diuresis, natriuresis, and calciuresis. (1998) (12)
- Normalization of organ bath contraction data for tissue specimen size: does one approach fit all? (2019) (12)
- NPY-stimulated Ca2+ mobilization in SK-N-MC cells is enhanced after isoproterenol treatment. (1992) (12)
- Drug-induced urinary incontinence. (2008) (12)
- ASSESSMENT OF CENTRAL NERVOUS SYSTEM ACCESS OF A NEW ANTIMUSCARINIC DRUG, FESOTERODINE (2009) (12)
- Regulation of GAPDH expression by treatment with the β-adrenoceptor agonist isoprenaline—is GADPH a suitable loading control in immunoblot experiments? (2015) (11)
- G-Protein coupling and signalling of Y1-like neuropeptide Y receptors in SK-N-MC cells (1991) (11)
- Loss of blood pressure control on withdrawal of fluconazole during nifedipine therapy. (1999) (11)
- Duloxetine in the Treatment of Stress Urinary Incontinence (2005) (11)
- Dissociation between phytohaemagglutinin-stimulated generation of inositol phosphates and Ca2+ increase in human mononuclear leucocytes. (1992) (11)
- Affinity profile at α1- and α2-adrenoceptor subtypes and in vitro cardiovascular actions of (+)-boldine (2002) (11)
- Urinary Bladder Weight and Function in a Rat Model of Mild Hyperglycemia and Its Treatment With Dapagliflozin (2019) (11)
- Drug- and disease-induced changes of human cardiac beta 1- and beta 2-adrenoceptors. (1989) (11)
- Disease states can modify both receptor number and signal transduction pathways. (1989) (11)
- Medical Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (2009) (11)
- Is SDZ NVI-085 an α1-adrenoceptor subtype-selective agonist? (1994) (11)
- Role of Transforming Growth Factor β in Rat Bladder Smooth Muscle Cell Proliferation (2007) (11)
- New medical developments in the management of LUTS in adult men (2006) (11)
- Sphingosine‐1‐phosphate and sphingosylphosphorylcholine: two of a kind? (2006) (11)
- Curriculum in Urology (1998) (11)
- Mitigation of β1- and/or β2-adrenoceptor function in human heart failure (1990) (11)
- Radioligand binding studies of alpha 1-adrenoceptor subtypes in rat heart. (1994) (11)
- Effect of prednisolone and ketotifen on beta 2-adrenoceptors in asthmatic patients receiving beta 2-bronchodilators. (1988) (11)
- Differential regulation of human alpha1-adrenoceptor subtypes. (1999) (10)
- Effects of insulin-induced hypoglycemia on beta 2-adrenoceptor density and proliferative responses of human lymphocytes. (1990) (10)
- Translocation of microfilament-associated inhibitory guanine-nucleotide-binding proteins to the plasma membrane in myeloid differentiated human leukemia (HL-60) cells. (1996) (10)
- Absorption of intravesically applied drugs: comparison of normal and ileal augmented rabbit bladder. (2004) (10)
- Does concomitant diabetes affect treatment responses in overactive bladder patients? (2013) (10)
- α1-adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy (1993) (10)
- Nifedipine inhibits sphinogosine-1-phosphate-induced renovascular contraction in vitro and in vivo. (2001) (10)
- α1B- but not α1A-adrenoceptors mediate inositol phosphate generation (1990) (10)
- β3-Adrenoceptors: a drug target in ophthalmology? (2013) (10)
- Neuropeptide Y enhances potassium excretion by mechanisms distinct from those controlling sodium excretion. (2000) (10)
- Polymorphisms in human muscarinic receptor subtype genes. (2012) (10)
- Re: Tamsulosin and the Risk of Dementia in Older Men with Benign Prostatic Hyperplasia. (2018) (10)
- Is bradykinin a mediator of renal neuropeptide Y effects? (1999) (10)
- How Can 1 + 1 = 3? β2-Adrenergic and Glucocorticoid Receptor Agonist Synergism in Obstructive Airway Diseases (2011) (9)
- Muscarinic receptor expression and receptor-mediated detrusor contraction: comparison of juvenile and adult porcine tissue (2008) (9)
- Lack of effect of chronic calcium antagonist treatment on beta 1- and beta 2-adrenoceptors in right atria from patients with or without heart failure. (1992) (9)
- [Guidelines of German urologists on therapy of benign prostate syndrome]. (2003) (9)
- Adrenoceptors—New roles for old players (2019) (9)
- How β3‐adrenoceptor‐selective is mirabegron? (2016) (9)
- Stimulation of mitogen activated protein kinase and cellular proliferation in renal proximal tubular cells. (1998) (9)
- Association of polymorphisms in CYP19A1 and CYP3A4 genes with lower urinary tract symptoms, prostate volume, uroflow and PSA in a population-based sample (2009) (9)
- Continence : current concepts and treatment strategies (2009) (9)
- Observational study on safety and tolerability of duloxetine in the treatment of female stress urinary incontinence in German routine practice. (2013) (9)
- Commentary on the BJP's new statistical reporting guidelines (2018) (8)
- Comparison of old and new IMX assays for monitoring of tacrolimus levels (1997) (8)
- Tolerability of amine uptake inhibitors in urologic diseases. (2006) (8)
- Can [125I]-Iodocyanopindolol Label β3-Adrenoceptors in Rat Urinary Bladder? (2010) (8)
- Adrenoceptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (8)
- Can you blame cold feet on Epac (and Rap1A)? Focus on "cyclic AMP-Rap1A signaling activates RhoA to induce α(2C)-adrenoceptor translocation to the cell surface of microvascular smooth muscle cells". (2012) (8)
- Synthesis and Evaluation in Rats of the Dopamine D2/3 Receptor Agonist 18F-AMC20 as a Potential Radioligand for PET (2015) (8)
- A mitogen-activated protein kinase is involved in the inotropic but not chronotropic actions of adrenoceptor agonists and endothelin-1 (2002) (8)
- Concepts and Principles of Pharmacology: 100 Years of the Handbook of Experimental Pharmacology (2019) (8)
- Comparison of cloned and pharmacologically defined rat tissue alpha 1-adrenoceptor subtypes. (1994) (8)
- Can a GDP-Liganded G-Protein Be Active? (2005) (8)
- 880 ASSESSMENT OF FESOTERODINE TREATMENT IN OLDER PEOPLE WITH OVERACTIVE BLADDER: RESULTS OF SOFIA, A DOUBLE-BLIND, PLACEBO- CONTROLLED PAN EUROPEAN TRIAL (2011) (8)
- alpha-blocker treatment of urolithiasis. (2006) (7)
- The effects of SB 216469, an antagonist which discriminates between the alpha 1A-adrenoceptor and the human prostatic alpha 1-adrenoceptor. (1996) (7)
- [Importance of beta 2-adrenergic receptors in heart failure]. (1992) (7)
- How significant are your data? The need for a culture shift (2014) (7)
- NPY and carbachol raise Ca2+ in SK-N-MC cells by three different mechanisms (1992) (7)
- α1-adrenoceptor activity of β-adrenoceptor ligands - An expected drug property with limited clinical relevance. (2020) (7)
- α1A and α1B-adrenoceptors enhance inositol phosphate generation in rat renal cortex (1993) (7)
- Tamsulosin modified-release and oral-controlled absorption system formulations in the treatment of benign prostatic hyperplasia (2006) (7)
- Comparison of clot lysis activity and biochemical properties of originator tenecteplase (Metalyse®) with those of an alleged biosimilar (2014) (7)
- Are "functionally related polymorphisms" of renin-angiotensin-aldosterone system gene polymorphisms associated with hypertension? (2010) (7)
- A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021 (2022) (7)
- EUROPEAN ASSOCIATION OF UROLOGY (2004) (7)
- [Dose-escalation of SSRIS in major depressive disorder. Should not be recommended in current guidelines]. (2010) (7)
- Cross-regulation between cardiac muscarinic acetylcholine receptors and β-adrenoceptors: lessons for use of knock-out mice (2012) (7)
- Desensitization of cAMP Accumulation via Human β3-Adrenoceptors Expressed in Human Embryonic Kidney Cells by Full, Partial, and Biased Agonists (2019) (7)
- Do β3-adrenoceptor agonists cause urinary bladder smooth muscle relaxation by inhibiting acetylcholine release? (2017) (7)
- L-type calcium current and contractility in ventricular myocytes from mice overexpressing the cardiac beta 2-adrenoceptor. (1999) (7)
- α‐ and β‐Adrenoceptors in Hypertension. I. Cardiac and Renal α1-, β1, and β2-Adrenoceptors in Rat Models of Acquired Hypertension (1989) (6)
- Synthesis and evaluation in rats of homologous series of [18F]-labeled dopamine D2/3 receptor agonists based on the 2-aminomethylchroman scaffold as potential PET tracers (2015) (6)
- [Anticholinergics for overactive bladder: does subtype selectivity play a role?]. (2006) (6)
- Editorial comment on: distribution and function of the hydrogen sulfide-sensitive TRPA1 ion channel in rat urinary bladder. (2008) (6)
- Factors Associated With Nocturia-Related Quality of Life in Men With Lower Urinary Tract Symptoms and Treated With Tamsulosin Oral Controlled Absorption System in a Non-Interventional Study (2020) (6)
- Post-marketing studies can make important contributions to medical knowledge (2012) (6)
- Effects of ketotifen on human lymphocytes in vitro and in vivo. (1993) (6)
- Sphingomyelin metabolism and endothelial cell function. (2007) (6)
- Transient receptor potential (TRP) channels as drug targets (2006) (6)
- OnabotulinumtoxinA: how deep will it go? (2014) (6)
- α‐ and β‐Adrenoceptors in Hypertension. II. Platelet α2- and Lymphocyte β2-Adrenoceptors in Children of Parents with Essential Hypertension. A Model for the Pathogenesis of the Genetically Determined Hypertension (1989) (6)
- Gender and hypertension interact to regulate neuropeptide Y receptor responsiveness (2000) (6)
- Muscarinic receptor subtype mRNA expression in the human prostate: association with age, pathological diagnosis, prostate size, or potentially interfering medications? (2014) (6)
- Effects of alniditan on neurogenic oedema in the rat dura mater and on contraction of rat basilar artery. (1999) (6)
- Functional and biochemical characterization of a calcium-ionophore-induced state of unresponsiveness in a cytolytic T cell clone. (1992) (6)
- The role of cyclic AMP in the positive inotropic effect mediated by beta 1- and beta 2-adrenoceptors in isolated human right atrium. (1987) (6)
- Novel teaching techniques in pharmacology (2002) (6)
- A Systematic Review of Inverse Agonism at Adrenoceptor Subtypes (2020) (6)
- Expectations and satisfaction of academic investigators in nonclinical collaboration with the pharmaceutical industry (2015) (6)
- Pharmacology and quantitative structure-activity relationships of imidazolylpropylguanidines with mepyramine-like substructures as non-peptide neuropeptide Y Y1 receptor antagonists. (2000) (6)
- Multiple gene approaches to delineate the role of the renin-angiotensin-aldosterone system in nephropathy. (2005) (5)
- Expression and Signaling of β-Adrenoceptor Subtypes in the Diabetic Heart (2020) (5)
- Why Are New Drugs Expensive and How Can They Stay Affordable? (2019) (5)
- [German guidelines for the assessment of BPH. What's new in 2007?]. (2008) (5)
- β-Adrenoceptor-mediated Relaxation of Urinary Bladder Muscle in β2-Adrenoceptor Knockout Mice (2016) (5)
- Agonist-Induced Desensitization of /-Adrenoceptor Function in Humans Subtype-Selective Reduction in fB1- or j82-Adrenoceptor-Mediated Physiological Effects by Xamoterol or Procaterol (2005) (5)
- Murine Alpha 1-Adrenoceptor Subtypes . I . Radioligand Binding Studies 1 (1998) (5)
- Protecting Bladder Function and Reducing Disease Progression (2003) (5)
- Efficacy of fesoterodine over 24 hours in subjects with overactive bladder (2010) (5)
- Neuropeptide Y and Drug Development (1998) (5)
- Do saw palmetto extracts block human alpha1-adrenoceptor subtypes in vivo? (2001) (5)
- Factors Associated with Decisions for Initial Dosing, Up-Titration of Propiverine and Treatment Outcomes in Overactive Bladder Syndrome Patients in a Non-Interventional Setting (2021) (5)
- The effect of elective sham dose escalation on the placebo response during an antimuscarinic trial for overactive bladder symptoms. (2012) (5)
- Building Robustness into Translational Research. (2019) (5)
- A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020 (2021) (5)
- Cyclic AMP-Rap 1 A signaling activates RhoA to induce 2 c-adrenoceptor translocation to the cell surface of microvascular smooth muscle cells (2012) (5)
- Affinity profile at alpha(1)- and alpha(2)-adrenoceptor subtypes and in vitro cardiovascular actions of (+)-boldine. (2002) (5)
- Is the glycogen synthase analogue C1-peptide a suitable fluorescent substrate for routine measurements of protein kinase C? (1995) (5)
- Endothelin-induced inositol phosphate formation in rat kidney. Studies on receptor subtypes, G-proteins and regulation during ontogenesis (1996) (5)
- Upregulation of β3-adrenoceptors—a general marker of and protective mechanism against hypoxia? (2019) (5)
- Preclinical research strategies for newly approved drugs as reflected in early publication patterns (2016) (5)
- Alpha 1 B- but not alpha 1 A-adrenoceptors mediate inositol phosphate generation. (1990) (5)
- Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression (2020) (5)
- Effects of alpha(1)-adrenoreceptor antagonists on pupil diameter and intraurethral pressure in rabbits (2006) (4)
- Longitudinal trends and subgroup analysis in publication patterns for preclinical data of newly approved drugs (2016) (4)
- Adrenergic Receptors in Clinical Medicine (2006) (4)
- [Drug-drug interactions in urology]. (2009) (4)
- [Management of geriatric patients with benign prostatic hyperplasia]. (2020) (4)
- Meeting report for the ASPET Ray Fuller Symposium: lower urinary tract disorders: physiology, pharmacology, and therapeutic approaches. (2002) (4)
- Differential vascular alpha1-adrenoceptor antagonism by tamsulosin and terazosin. (1999) (4)
- Defective signal transduction in T lymphocytes. (1989) (4)
- From α2-adrenoceptors to imidazoline receptors : putative progress for cardiovascular therapy (1992) (4)
- Candidate genes for the hereditary component of cardiac hypertrophy. (2006) (4)
- Agonist signalling properties of radiotracers used for imaging of dopamine D2/3 receptors (2014) (4)
- Beta2-adrenergic receptor gene polymorphisms: will the important one please step forward? (2008) (4)
- — SPECIAL SECTION ON HIGHLIGHTS FROM IUPHAR The Odd Sibling : Features of b 3-Adrenoceptor Pharmacology (2014) (4)
- 50 EFFECTS OF OUTLET OBSTRUCTION ON RAT BLADDER CONTRACTION AND RELAXATION BY ADRENOCEPTOR AGONISTS (2007) (4)
- Impact of guideline awareness in public pharmacies on counseling of patients with acute or chronic constipation in a survey of pharmacy personnel (2020) (4)
- Cardiac and Vascular α1-Adrenoceptors in Congestive Heart Failure: A Systematic Review (2020) (4)
- The centrally acting ion channel modulator flupirtine improves bladder function in animal models and patients with overactive bladder syndrome (2008) (4)
- Protocol for a systematic review of guidelines for rigour in the design, conduct and analysis of biomedical experiments involving laboratory animals (2018) (4)
- Room B, 10/17/2000 9: 00 AM - 11: 00 AM (PS)(S+)-Ketamine Increases Muscle Sympathetic Activity and Maintains the Sympathetic Response to Hypotensive Challenges A-160 (2000) (4)
- Do overactive bladder symptoms exhibit a Gaussian distribution? Implications for reporting of clinical trial data (2018) (3)
- 331 SILODOSIN CONSISTENTLY IMPROVES NOCTURIA IN MEN WITH LUTS SUGGESTIVE OF BPH. ANALYSIS OF THREE PHASE III PLACEBO-CONTROLLED STUDIES (2011) (3)
- Does verapamil act as an immunomodulatory drug in vivo? (1991) (3)
- Editorial guidelines for manuscripts on the pharmacology of plant extracts (2005) (3)
- Neuropeptide Y and its antagonists (1992) (3)
- Increased beta 2-adrenoreceptor density in heart, kidney and lung of spontaneously hypertensive rats. (1987) (3)
- Neuropeptide Y and the Kidney (2004) (3)
- In vitro and in vivo uroselectivity of B8805-033, an antagonist with high affinity at prostatic alpha1A- vs. alpha1B- and alpha1D-adrenoceptors. (2001) (3)
- Validation of Fenoterol to Study β2-Adrenoceptor Function in the Rat Urinary Bladder (2021) (3)
- Innovation in cardiovascular disease in Europe with focus on arrhythmias: current status, opportunities, roadblocks, and the role of multiple stakeholders. (2018) (3)
- Alpha 1A and alpha 1B-adrenoceptors enhance inositol phosphate generation in rat renal cortex. (1993) (3)
- Interaction between alpha 2-adrenergic and NPY receptor pathways in human erythroleukemia cells. (1989) (3)
- Pathophysiological Factors in the Relationship between Chronological Age and Calculated Lung Age as Detected in a Screening Setting in Community-Dwelling Subjects (2016) (3)
- Revised editorial guidelines for manuscripts on the pharmacology of plant extracts (2017) (3)
- Established and emerging treatments for diabetes-associated lower urinary tract dysfunction (2022) (3)
- Do review articles boost journal impact factors? A longitudinal analysis for five pharmacology journals (2018) (3)
- Choice of y-axis can mislead readers (2020) (3)
- Comparison of α1A- and α1B-adrenoceptor coupling to inositol phosphate formation in rat kidney (1994) (3)
- Adrenoceptors in GtoPdb v.2021.3 (2021) (3)
- Treatment of Bladder Pain Syndrome: One Size May Not Fit All. (2018) (3)
- Model‐based meta‐analysis of the time to first acute urinary retention or benign prostatic hyperplasia‐related surgery in patients with moderate or severe symptoms (2020) (3)
- [New pharmacological treatment concepts for overactive bladder]. (2003) (3)
- Adrenergic Control of Circulating Lymphocyte Subpopulations (2013) (2)
- Erratum to: Rat β3-adrenoceptor protein expression: antibody validation and distribution in rat gastrointestinal and urogenital tissues (2014) (2)
- DO M2-MUSCARINIC RECEPTORS CONTRIBUTE TO HUMAN BLADDER FUNCTION IN VIVO? (2009) (2)
- Neuropeptide Y receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (2)
- What Are Realistic Expectations to Become Free of Overactive Bladder Symptoms? Experience from Non-interventional Studies with Propiverine (2022) (2)
- Ontogenesis of Sympathetic Responsiveness in Spontaneously Hypertensive Rats I . Renal a ,-, as-, and / 3-Adrenergic Receptors and Their Signaling (2005) (2)
- [alpha 1-receptor blockade in therapy of benign prostatic hyperplasia syndrome. Correct dosing for optimal effectiveness]. (2002) (2)
- Evaluation of [18F]AMC-15, [18F]FPr-AMC-13 and [18F]FEt-AMC-13 as candidate dopamine D2/3-agonist radioligands for PET (2013) (2)
- On the Role of Renal ar-Adrenergic Receptors in Spontaneously Hypertensive Rats (2005) (2)
- Expression of Renal α1 - Adrenergic Receptor Subtypes in Established Hypertension (1992) (2)
- Use of Antibodies in the Research on Muscarinic Receptor Subtypes (2016) (2)
- Lymphocyte adenylate cyclase activity in immunosuppressed patients (1989) (2)
- An anthology from Naunyn-Schmiedeberg’s Archives of Pharmacology (2006) (2)
- Are β3‐adrenoceptor gene polymorphisms relevant for urology? (2022) (2)
- [Do benign prostatic hyperplasia drugs affect mood or cognition?] (2019) (2)
- Reproducibility of preclinical data: one man's poison is another man's meat (2016) (2)
- Stability of cyclosporin in blood upon shipping-related extended storage. (1995) (2)
- MP-04.09: Cardiovascular safety of solifenacin in routine clinical use (2006) (2)
- Normalization of organ bath contraction data for tissue specimen size: does one approach fit all? (2019) (2)
- [What does "intraoperative floppy iris" syndrome mean for urologists?]. (2006) (2)
- Cellular basis of detrusor smooth muscle contraction (2016) (2)
- The effect of paroxetine on amygdala reactivity after emotional faces measured with fMRI (2008) (2)
- Lack of desensitization of α-and β-adrenoceptor function during chronic treatment of healthy volunteers with ibopamine, an orally active dopamine receptor agonist (1993) (2)
- [3H]-Spiperone Competition Binding to Dopamine D2, D3 and D4 Receptors (2013) (2)
- [Anticholinergic treatment of overactive bladder syndrome. Is it all the same?]. (2009) (2)
- Evidence-based management of overactive bladder patients: Expectation to become symptom-free (2018) (2)
- [Medical therapy of urinary incontinence]. (2004) (2)
- Platelet adenylyl cyclase signaling remains unaltered in children undergoing hemodialysis treatment (2001) (2)
- Cytoskeletal inhibitors impair Ca2+ elevations via neuropeptide Y and other Gi-coupled receptors. (1996) (2)
- Experimental and clinical nephroprotection by the xanthine oxidase inhibitor febuxostat (2016) (2)
- [Sildenafil--adverse effects, complications and safety]. (2002) (2)
- Randomized, Placebo-Controlled, Double-Blind and Open-Label Studies in the Treatment and Prevention of Acute Diarrhea With Enterococcus faecium SF68 (2020) (2)
- as-Adrenergic Receptor Stimulation Mobilizes Intracellular Cas + in Human Erythroleukemia Cells (2001) (2)
- Impact of the Neck and/or Shoulder Pain on Self-reported Headache Treatment Responses – Results From a Pharmacy-Based Patient Survey (2022) (2)
- Is SDZ NVI-085 an alpha 1-adrenoceptor subtype-selective agonist? (1994) (2)
- Re: A Randomized Controlled Study of the Efficacy of Tamsulosin Monotherapy and its Combination with Mirabegron for Overactive Bladder Induced by Benign Prostatic Obstruction (2016) (2)
- DOES TIME OF ADMINISTRATION (MORNING VS. EVENING) AFFECT TAMSULOSIN TOLERABILITY (1999) (2)
- Function and morphology of the urinary bladder after denervation. (2021) (2)
- Analysis of 16 studies in nine rodent models does not support the hypothesis that diabetic polyuria is a main reason of urinary bladder enlargement (2022) (2)
- Are blood vessels a target to treat lower urinary tract dysfunction? (2015) (2)
- Denominator changes may obscure results from single-well assays: β3-adrenoceptor ligand-induced changes of cell number as example (2017) (1)
- Pertussis Toxin Treatment of Whole Blood (2005) (1)
- 520 THE BETA-3 ADRENOCEPTOR AGONIST SOLABEGRON IS EFFECTIVE AND SAFE FOR IMPROVING SYMPTOMS OF OVERACTIVE BLADDER (2012) (1)
- Editorial Comment. (2016) (1)
- 685 The beta-3 adrenoceptor agonist solabegron is safe and effective for improving symptoms of overactive bladder (2012) (1)
- w -Phenyl-w -(2-pyridyl)alkyl-substituted bisguanidines are moderate neuropeptide Y antagonists (1996) (1)
- Erratum to “Muscarinic receptors stimulate cell proliferation in the human urothelium-derived cell line UROtsa” [Pharmacol. Res. 64 (2011) 420–425] (2015) (1)
- Ex Vivo Characterization of a Novel Iodine-123-Labelled Aminomethylchroman as a Potential Agonist Ligand for SPECT Imaging of Dopamine D2/3 Receptors (2014) (1)
- 578 Effect of treatment response on the decision to escalate antimuscarinic dose in elderly subjects with overactive bladder (2012) (1)
- DESPITE SIMILAR NEUROENDOCRINE AND CARDIOVASCULAR EFFECTS PROPOFOL DECREASES WITHDRAWAL SYMPTOMS FOLLOWING OPIOID DETOXIFICATION OF ADDICTED PATIENTS DURING GENERAL ANESTHESIA (1998) (1)
- UROTHELIAL RELEASE OF NERVE GROWTH FACTOR (NGF): MODULATION BY PROTEIN KINASE C AND MITOGEN-ACTIVATED PROTEIN KINASE PATHWAYS (2011) (1)
- Although the phosphodiesterase inhibitors have revolutionised the treatment of ED, postoperative ED due to nerve damage remains a therapeutic challenge. (2007) (1)
- Lower urinary tract disorders - Ray Fuller Symposium. (2002) (1)
- Sildenafil (Viagra®) • Tolerability, contraindications and drug interactions (1999) (1)
- [Sildenafil (Viagra). Tolerance, contraindications, drug interactions]. (1999) (1)
- Re: The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. (2017) (1)
- Can open-label studies demonstrate efficacy in improving sexual function? (2009) (1)
- Editorial: G Protein-Coupled Receptor Kinases (GRKs) and β-Arrestins: New Insights Into Disease Regulators (2020) (1)
- 571Cardiostimulant Effects of Mirabegron in Human Atrium and Ventricle In Vitro (2017) (1)
- Publication trends in Naunyn-Schmiedeberg’s Archives of Pharmacology: focus on pharmacology in Egypt (2013) (1)
- f-Adrenergic Receptors in Lymphocyte Subsets After Exercise Alterations in Normal Individuals and Patients With Congestive Heart Failure* (2005) (1)
- Comparison of alpha 1A- and alpha 1B-adrenoceptor coupling to inositol phosphate formation in rat kidney. (1994) (1)
- Words of Wisdom: Re: A Randomized Controlled Study of the Efficacy of Tamsulosin Monotherapy and its Combination with Mirabegron for Overactive Bladder Induced by Benign Prostatic Obstruction. (2016) (1)
- Does treatment with beta-adrenoceptor antagonists in vivo alter human adenylate cyclase responsiveness in vitro? (1991) (1)
- Comparison of [3H]tamsulosin and [3H]prazosin binding to wild-type and constitutively active alpha1B-adrenoceptors. (2000) (1)
- Is cyclic AMP formation desensitized in patients with end-stage renal failure? (2005) (1)
- Are today’s nocturia patients the former bedwetters? An internet-based national epidemiological survey (2011) (1)
- MP-09.10 (2006) (1)
- NPY and carbachol raise Ca z + in SK-NMC cells by three different mechanisms Evidence for inositol phosphate-independent Ca z÷ mobil ization by N P Y (1)
- Efficacy and Tolerability of Fesoterodine in Older People With Overactive Bladder: Results of the Open-Label Phase of the SOFIA Trial (2011) (1)
- MP-09.11 (2006) (1)
- Lack of desensitization of alpha- and beta-adrenoceptor function during chronic treatment of healthy volunteers with ibopamine, an orally active dopamine receptor agonist. (1993) (1)
- Weak association between arterial hypertension and overactive bladder baseline symptoms and treatment responses (2022) (1)
- [Adrenoreceptor subtypes--function and significance]. (1993) (1)
- [Pharmacotherapy of stress incontinence]. (2005) (1)
- Study Designs for Evaluation of Combination Treatment: Focus on Individual Patient Benefit (2022) (1)
- Associations between the Patient Perception of Bladder Condition score and overactive bladder syndrome symptoms at baseline and upon treatment (2022) (1)
- Emerging country pharmacology: a 10-year perspective from Naunyn-Schmiedeberg’s Archives of Pharmacology (2011) (1)
- Randomized dose escalation of paroxetine in depressed patients visualized by [123I]β-CIT SPECT (2008) (1)
- Statistical inference in abstracts of 3 influential clinical pharmacology journals analysed using a text‐mining algorithm (2021) (1)
- Clinical pharmacology of functional disorders of the urogenital system. (2011) (1)
- An invitation for comprehensive single-compound reviews on the pharmacological properties of newly launched drugs (2013) (1)
- What do we really know about benign prostatic hyperplasia and lower urinary tract symptoms in adult men? (2011) (1)
- UvA-DARE ( Digital Academic Repository ) Association of polymorphisms in CYP 19 A 1 and CYP 3 A 4 genes with lower urinary tract symptoms , prostate volume , uroflow and PSA in a population-based sample (2017) (1)
- Pharmacokinetics of Ambroxol Sustained Release (Mucosolvan® Retard) Compared with Other Formulations in Healthy Volunteers (2020) (1)
- Self-Medication for the Treatment of Abdominal Cramps and Pain—A Real-Life Comparison of Three Frequently Used Preparations (2022) (1)
- An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system. (Department of Neurology, University of Essen, Essen, Germany) Pain. 2001;92:101–106. (2001) (1)
- Re: Ghost writers in the sky. (2008) (0)
- An invitation for comprehensive single-compound reviews on the pharmacological properties of newly launched drugs (2013) (0)
- Noradrenergic neurons: edited by Marianne Fillenz, Cambridge University Press, 1990. £30.00 hbk, £10.95 pbk (238 pages) ISBN 0 521 24546 X hbk, 0 521 28780 4 pbk (1991) (0)
- Impact of Formulation on the Pharmacokinetic Profile of Dutasteride (2016) (0)
- Issue Information (2019) (0)
- Is agonist-induced beta-adrenoceptor down-regulation always accompanied by increases in G-i-protein? (1994) (0)
- Septic shock: A role for RGS proteins? (2008) (0)
- Ejaculatory dysfunction and alpha-adrenoceptor antagonists. (2004) (0)
- Muscarinic bladder responsiveness declines with age in humans and rats: Roles of receptor number and subtypes (2003) (0)
- Developmental expression patterns of Epac proteins in the mouse heart (2006) (0)
- Conservative Treatment of Benign Prostatic Hyperplasia: In Reply (2008) (0)
- Lower urinary tract disorders - Ray Fuller Symposium. Physiology, pharmacology and therapeutics approaches. (2002) (0)
- SC11 QSAR of Y1-receptor antagonistic imidazolylpropylguanidines derived from arpromidine and mepyramine (1994) (0)
- [How can innovative medicines stay affordable?] (2017) (0)
- Correlation of pad use with specific overactive bladder symptoms: findings at baseline and after treatment in two non-interventional studies (2019) (0)
- Correction to: A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021 (2022) (0)
- Is Muscarinic Receptor mRNA Expression in the Human Prostate Associated with Genotype for the M2 Receptor? (2012) (0)
- WITHDRAWN: Is nebivolol a beta(3)-adrenoceptor agonist? (2008) (0)
- 881 TREATMENT OF MALE OAB WITH PROPIVERINE ER-DOES COMBINATION WITH A-BLOCKERS CHANGE EFFICACY OR SAFETY? (2011) (0)
- Editorial comment on: Intraprostatic and bladder-neck botulinum A toxin in treatment of males with bladder-neck dyssynergia: a pilot study. (2008) (0)
- 761Decreased bladder capacity in animals prone to overactive bladder: Are the bladders too small? (2005) (0)
- Do patient perception and objective symptoms correlate in patients with overactive bladder syndrome? An analysis based on Patient Perception of Bladder Condition (2019) (0)
- Perspectives of Pharmacology over the Past 100 Years. (2019) (0)
- Cardiovascular pharmacology — a time to integrate (2007) (0)
- Prof. Otto‐Erich Brodde, PhD (2008) (0)
- Reply (2010) (0)
- PD33-02 IMPACT OF EARLY VS. DELAYED INITIATION OF DUTASTERIDE/TAMSULOSIN COMBINATION THERAPY IN LOWER URINARY TRACT SYMPTOMS/BENIGN PROSTATIC HYPERPLASIA (LUTS/BPH) PATIENTS WITH MODERATE TO SEVERE SYMPTOMS AT RISK FOR PROGRESSION (2020) (0)
- BETA-ADRENOCEPTOR AGONISTS EFFECTIVELY RELAX RAT BLADDER IRRESPECTIVE OF CONTRACTILE STIMULUS (2006) (0)
- [3H]-Spiperone Saturation Binding to Dopamine D2, D3 and D4 Receptors (2013) (0)
- Regulation of G protein-coupled receptor signalling: Focus on the cardiovascular system and regulator of G protein signalling proteins. A general introduction (2009) (0)
- 778 EVALUATION OF FESOTERODINE EFFICACY OVER 24 HOURS FOLLOWING ONCE-DAILY DOSING IN SUBJECTS WITH OVERACTIVE BLADDER (2010) (0)
- Implications for Congestive Heart Failure (2005) (0)
- WITHDRAWN: Is nebivolol a β3-adrenoceptor agonist? (2008) (0)
- Di!erential agonist-induced regulation of the sphingosine- 1-phosphate receptor subtypes 1 and 3 (S1P1 and S1P3) (2009) (0)
- Is antimuscarinic treatment of overactive bladder symptoms effective and safe in elderly patients (2010) (0)
- Lack of effect of chronic calcium antagonist treatment on ,-and 2-adrenoceptors in right atria from patients with or without heart failure (2006) (0)
- Obituary: Prof. Otto-Erich Brodde, PhD (2008) (0)
- University of Groningen Agonist signalling properties of radiotracers used for imaging of dopamine D-2 / 3 receptors (2017) (0)
- Editorial comment. (2011) (0)
- Population-based analysis of the relationship between falls, fractures and nocturia (2018) (0)
- β3-Adrenoceptors: a drug target in ophthalmology? (2013) (0)
- 103. Are renal α-adrenoceptor alterations a major cause of genetic hypertension in the spontaneously hypertensive rat? (1991) (0)
- Are overactive bladder symptoms related to the presence of arterial hypertension (2009) (0)
- Synthesis and evaluation of [F-18]AMC-13 and [F-18]AMC-15-novel candidate dopamine D-2/3-agonist tracers for positron emission tomography (PET) (2013) (0)
- EDITORIAL COMMENT. (2020) (0)
- Autoaugmentation versus Ileumaugmentation der neurogenen Hochdruckblase: Ergebnisse einer prospektiv-randomisierten tierexperimentellen Untersuchung1 - Autoaugmentation versus ileal augmentation of the neurogenic bladder: results of a prospective-randomized animal trial - (2000) (0)
- Catecholamines inhibit early steps of lymphocyte activation (1990) (0)
- Chronic &mgr;-Opioid Receptor Stimulation in Humans Decreases Muscle Sympathetic Nerve Activity (2001) (0)
- Discussion of draft IUPHAR guidelines on design, analysis andreporting of studies in experimental pharmacology (2018) (0)
- Chance of OAB patients to become symptom-free upon anti-muscarinic treatment depends on age and gender (2019) (0)
- Pharmacology of Sexual Function (2011) (0)
- Characterization of 123I-and 18F-labeled radiopharmaceuticals for imaging dopamine D2-receptors in the high-affinity state (2013) (0)
- THE MUSCARINIC RECEPTOR ANTAGONIST PROPIVERINE BINDS TO HUMAN ALPHA-1-ADRENOCEPTORS AND RELAXES THE HUMAN PROSTATE (2009) (0)
- Do gender or age affect the therapeutic response to tolterodine (2002) (0)
- Current and emerging pharmacological targets and treatments of urinary incontinence and related disorders. (2023) (0)
- Should overactive bladder symptoms be reported as means or medians? An exploratory study with propiverine (2018) (0)
- Issue Information (2020) (0)
- Editorial Comment. (2021) (0)
- [Contemporary medical management of the benign prostatic syndrome]. (2008) (0)
- Y-2 Neuropeptide Y Receptor (2008) (0)
- NPY-like peptides, their receptors and gastrointestinal function (2004) (0)
- Investigation of α1A- and α1B-adrenoceptors of the rat brain by highly subtype-selective antagonists☆ (1990) (0)
- [The medication-induced dysfunction of the urinary bladder]. (2003) (0)
- Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patients (2023) (0)
- A pharmaceutical composition for the treatment of stress incontinence and / or mixed incontinence (2003) (0)
- Medications and Drug Targets for the Treatment of Diseases of the Urinary Bladder and Urethra (2021) (0)
- 380 Right ventricular failure: peak of myocyte death precedes clinical signs (2007) (0)
- α1-Adrenergic Receptors of MDCK-D1 Cells Utilize Multiple Signalling Components (2002) (0)
- Experimental and clinical nephroprotection by the xanthine oxidase inhibitor febuxostat (2016) (0)
- Is verapamil an inimunosuppressive drug in vivo (1990) (0)
- Cardiovascular, Urinary and Respiratory Pharmacology: Overview (2021) (0)
- A pharmaceutical composition of a beta-3-adrenoceptor agonist and a serotonin and / or norepinephrine reuptake inhibitor and their use for the treatment of blasenfunktionsstoerungen (2003) (0)
- A pharmaceutical composition of a beta-3-adrenoceptor agonist and an alpha agonists (2003) (0)
- How much potential for transient receptor potential channels in the bladder? (2015) (0)
- farmaceutica based adrenergic receptor agonist and a beta-3 inhibitor of serotonin reuptake and / or norepinephrine and their use for the treatment of functional disorders of the urinary bladder composition. (2003) (0)
- Conservative Treatment of Benign Prostatic Hyperplasia Part 2 in a Series on Benign Prostatic Hyperplasia (2007) (0)
- [Concerning: "Behavioral neurology as basis of neurorehabilitation" by J. Kesselring (Schweiz. med. Wschr. 19912; 122: 1197-1205)]. (1993) (0)
- role of acetylcholine as a growth factor: focus on human urinary bladder (2014) (0)
- Correlations of mean voided volume with other parameters of overactive bladder syndrome (2023) (0)
- Renal G proteins in male and female rats Ontogenesis of sympathetic responsiveness in spontaneously hypertensive rats. II. (2011) (0)
- Doestreatment with-adrenoceptor antagonists invivoalter humanadenylate cyclase responsiveness invitro? (1991) (0)
- Bradykinin may be involved in neuropeptide Y-induced diuresis, natriuresis, and calciuresis. (1998) (0)
- β-Adrenoceptor Antagonists (2021) (0)
- [The overactive bladder--a case for the urologist]. (2003) (0)
- Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy in LUTS/BPH patients with moderate-severe symptoms at risk of disease progression: Results from clinical trial simulations using risk of AUR or BPH-related surgery (2020) (0)
- Serotonin transporter (SERT) polymorphism modifies the association between SERT occupancy and paroxetine treatment response: A [123I]β-CIT SPECT study (2008) (0)
- Authors' response to Hermann et al. Minimum quality criteria are needed in the assessment and communication of unexpected drug safety findings of marketed products from RCTs. (2012) (0)
- Does coupling to ADP ribosylation factor 6 explain differences between muscarinic and other receptors in interaction with β-adrenoceptor-mediated smooth muscle relaxation? (2022) (0)
- ENDOTHELIN-A-RECEPTOR ANTAGONIST INHIBITS ANGIOTENSIN II AND NORADRENALINE INDUCED VASO-CONSTRICTION IN HUMAN SKIN MICROCIRCULATION IN VIVO: P3.197 (2000) (0)
- A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022 (2023) (0)
- Safety and Tolerability of Duloxetine in the Treatment of Female Stress Urinary Incontinence (SUI) in General Practice in Germany - Results from a Large Observational Study (2009) (0)
- Duloxetine – three birds with one stone? (2007) (0)
- A comparison of normalization approaches for in vitro contraction experiments of urinary bladder (2018) (0)
- Insulin is Not Driving Urinary Bladder Enlargement in Rodent Models of Diabetes (2022) (0)
- Muscarinic receptor subtype mRNA expression in the human prostate: association with age, pathological diagnosis, prostate size, or potentially interfering medications? (2013) (0)
- 843Tamsulosin oral controlled absorption system (TOCAS) shows less inhibition of phenylephrine (PE) induced vasoconstriction than tamsulosin modified release (MR) (2005) (0)
- Expectations and satisfaction of academic investigators in nonclinical collaboration with the pharmaceutical industry (2015) (0)
- Re: PIEZO2 in Sensory Neurons and Urothelial Cells Coordinate Urination. (2021) (0)
- Pharmacotherapy of Urgency Incontinence (2009) (0)
- Y-4 Neuropeptide Y Receptor (2008) (0)
- Sa1790 Comparative Clinical Studies Between Racecadotril and Loperamide or Saccharomyces Boulardii in Adult Patients With Acute Diarrhea (2015) (0)
- Y-1 Neuropeptide Y Receptor (2008) (0)
- Impact of diabetes, hypertension, and their combination on basal symptoms and treatment responses in overactive bladder patients (2023) (0)
- A comparison of urinary bladder weight in male and female mice across five models of diabetes and obesity (2023) (0)
- Characterization of differential patient profiles and therapeutic responses of pharmacy customers for four ambroxol formulations (2018) (0)
- Longitudinal trends and subgroup analysis in publication patterns for preclinical data of newly approved drugs (2015) (0)
- What Do Academic Investigators Want and Get from Preclinical Collaboration with the Pharmaceutical Industry? (2015) (0)
- Use of guanidine derivatives for the preparation of a medicament with NPY-antagonistic effect (1990) (0)
- [Medical treatment of male lower urinary tract symptoms: what's new?] (2022) (0)
- Effects of concomitant diabetes on treatment responses to a muscarinic antagonist in overactive bladder patients (2010) (0)
- Protein Kinase C Does Not Mediate Phenylephrine-Induced Down-regulation of Madin-Darby Canine Kidney Cell Alpha-1 B Adrenoceptors 1 (1998) (0)
- Challenges in the Pharmacotherapy of Urogenital Disorders (2010) (0)
- Sex and Race Differences in Electrocardiogram Use (The National Hospital Ambulatory Medical Care Survey) (2001) (0)
- Faculty Opinions recommendation of Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study. (2006) (0)
- Impact of Neck and/or Shoulder Pain on Headache (2020) (0)
- Which measures of overactive bladder symptom treatment correlate best with patient satisfaction (2008) (0)
- Editorial Comment from Dr Michel to Expression and functional role of β3‐adrenoceptors in the human ureter (2013) (0)
- Anger: Adrenaline receptors do not allow us to be too sinful (2013) (0)
- A teaching tool about the fickle p value and other statistical principles based on real-life data (2021) (0)
- Publication trends in Naunyn-Schmiedeberg’s Archives of Pharmacology: focus on pharmacology in Egypt (2013) (0)
- Revisiting the relationship between overactive bladder syndrome and the frequency-urgency syndrome (2019) (0)
- Preclinical research strategies for newly approved drugs as reflected in early publication patterns (2015) (0)
- DOES AGE, GENDER OR CONCOMITANT DISEASE AFFECT THE SAFETY AND EFFICACY OF TELMISARTAN?: P 220 (2004) (0)
- {beta}3-Adrenergic receptor gene polymorphisms and lower urinary tract function (2009) (0)
- Is Dipstick Urinalysis Screening Beneficial in Men with Lower Urinary Tract Symptoms? (2019) (0)
- The Effects of Low-dose Empagliflozin on Cardiac Function in a Rat Model of Streptozotocin-induced Diabetes (2021) (0)
- Editorial Comment. (2020) (0)
- 1550: Do A-Blockers Reduce LUTS by Decreasing BOO? (2007) (0)
- P.2.c.039 Noradrenergic uptake inhibition of higher doses of paroxetine in relation to clinical efficacy: the DELPHI-study (2010) (0)
- Effects of Nifedipine on Renal and Cardiovascular Responses to Neuropeptide Y in Anesthetized Rats (2021) (0)
- Association of polymorphisms in CYP 19 A 1 and CYP 3 A 4 genes with lower urinary tract symptoms , prostate volume , uroflow and PSA in a population-based sample (2009) (0)
- Issue Information (2020) (0)
- The author currently is an employee of Boehringer Ingelheim. (2015) (0)
- Y-6 Neuropeptide Y Receptor (2008) (0)
- Rat renal alpha 1-adrenoceptor subtypes: characterization, function, and regulation. (1996) (0)
- Uncovering a role of β3-adrenoceptors in control of bladder size (2021) (0)
- A survey on the preferred use of CME activities by healthcare professionals in urological care (2019) (0)
- 604 □3-ADRENOCEPTOR GENE POLYMORPHISMS AND LOWER URINARY TRACT FUNCTION (2009) (0)
- [Essential hypertension: also a disease of the adrenoreceptors?]. (1990) (0)
- Faculty Opinions recommendation of Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized, double-blind, placebo-controlled study (ZD0947IL/0004). (2006) (0)
- Issue Information (2021) (0)
- for neuropeptide Y: subtypes and multiple second messengers (1991) (0)
- Synthesis And Preliminary Evaluation Of [18F]AMC-20 As Candidate Dopamine D2/3-Agonist Radioligand For PET (2013) (0)
- Y-5 Neuropeptide Y Receptor (2008) (0)
- Adrenoceptors: a convergence of thinking. (2002) (0)
- Hope for Disease-Modifying Treatment of Systemic Sclerosis/Scleroderma (2014) (0)
- Chapter 13 Medical treatment of LUTS and BPH (2011) (0)
- MP-09.12 (2006) (0)
- MOXONIDINE REDUCES THE BASAL TONE OF SNS ACTIVITY WITHOUT AN ADDITIONAL EFFECT ON EXERCISE AND MENTAL STRESS INDUCED SNS ACTIVATION: P3.39 (2000) (0)
- [Greek small letter beta]-BLOCKER TREATMENT DOES NOT AFFECT ADENYLATE CYCLASE RESPONSES TO [Greek small letter beta]-ADRENOCEPTOR DEPENDENT AND INDEPENDENT STIMULATION IN ATRIAL MYOCARDIUM FOLLOWING CARDIAC SURGERY (1998) (0)
- University of Groningen Hunting for the high-affinity state of G-protein-coupled receptors with agonist tracers (2019) (0)
- Chronic m-Opioid Receptor Stimulation in Humans Decreases Muscle Sympathetic Nerve Activity (2001) (0)
- Inhibition of sphingosine kinase induces vasoconstriction in isolated carotid arteries obtained from spontaneous hypertensive but not normotensive rats (2008) (0)
- 51 ASSOCIATION OF A POLYMORPHISM IN THE CYP3A4-GENE WITH BENIGN PROSTATIC HYPERPLASIA IN A POPULATION BASED SAMPLE (2007) (0)
- University of Groningen β 3-Adrenoceptor-mediated relaxation of rat and human urinary bladder (2015) (0)
- Trust me – I’m a scientist: Trust is fundamental in science. More often than not, we design our experiments at least in part based on data published by others. We trust them to be true, unless proven otherwise. (2016) (0)
- Regulation of Cardiac j 3-Adrenergic Receptors by Captopril Implications for Congestive Heart Failure (2005) (0)
- P14 FURTHER MECHANISMS FOR MICTURITION DYSFUNCTION AND TREATMENTWednesday, 18 March, 14.30-16.00, Room C4228 DO M2-MUSCARINIC RECEPTORS CONTRIBUTE TO HUMAN BLADDER FUNCTION IN VIVO? (2009) (0)
- Shaping the Evolution of CME towards better Outcomes: Proceedings of the 2018 ISSECAM Colloquium (2019) (0)
- Urinary bladder enlargement across nine rodent models of diabetes: correlations with glucose and insulin levels (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Martin Christian Michel?
Martin Christian Michel is affiliated with the following schools:
